查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1868925

标靶治疗市场按产品类型、给药途径和最终用户划分 - 全球预测 2025-2032

Targeted Therapy Market by Product Type, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，标靶治疗市场将成长至 1,218 亿美元，复合年增长率为 7.72%。

关键市场统计数据
基准年 2024 671.6亿美元
预计年份：2025年 724.1亿美元
预测年份 2032 1218亿美元
复合年增长率 (%) 7.72%

简明扼要地概述了不断发展的标靶治疗生态系统，将科学突破与领导者的营运、监管和商业要务联繫起来。

透过将分子层面的洞见与治疗方案设计相结合，标靶治疗正在重新定义临床医生和研发人员应对复杂疾病的方式。近年来，包括抗体药物复合体、单株抗体、蛋白质降解剂和小分子抑制剂在内的多种治疗方法取得了突破性进展，从概念验证阶段迈向了日益成熟的临床计画。因此，药物发现、开发和商业化等各环节的相关人员必须适应更快的迭代週期、更深入的生物标记整合以及更为细緻的监管互动。本文概述了影响该领域发展的关键因素，并展望了近期战术性重点。

科学、监管和商业性创新相互融合，正在重塑标靶治疗领域的治疗方法和业务重点。

过去几年，标靶治疗领域发生了翻天覆地的变化，加速了新型治疗方法的研发，同时也带来了新的营运挑战。蛋白质工程和偶联化学技术的进步使得抗体药物复合体（ADC）成为选择性递送细胞毒性药物的主要治疗方法。同时，单株抗体向全人源化和人源化结构的演进降低了免疫抗原性，延长了治疗疗程。此外，分子胶（MG）和蛋白水解靶向嵌合体（PTC）等标靶蛋白水解技术的成熟，为调控以往难以标靶的标靶开闢了新的途径，拓展了治疗选择。

分析2025年公布的累积贸易和关税趋势及其对生物製药采购、生产和患者获取策略的连锁影响

2025年宣布的累积关税和贸易调整措施的实施，为标靶治疗价值链带来了新的复杂性，影响采购、生产和分销决策。原料、特殊试剂和某些生物製药成分的关税变化推高了实际到岸成本，促使采购团队重新评估其供应商布局。这种压力通常会导致与契约製造的谈判週期延长，并促使企业重新关注双重筹资策略，以维持临床和商业性的连续性。此外，关税带来的成本压力也影响新设施建设和技术投资的资本分配决策。

整合产品模式、给药途径和终端用户交付方式等细分市场洞察，以指导研发优先排序和商业化策略。

有效的细分能够识别具有治疗获益和商业性回报的领域，从而实现跨产品、给药途径和最终用户领域的投资组合优先排序。依产品类型划分，抗体药物复合体(ADC)、单株抗体、蛋白水解物和小分子抑制剂可分为不同的类别，每种类别都有不同的开发、生产和商业化要求。在抗体药物复合体(ADC) 中，靶向 CD22 和 HER2 的药物在有效载荷选择和目标结合策略上存在差异，这会影响连接子化学和细胞毒性有效载荷的选择。单株抗体进一步细分为嵌合体、全人源型和人源化型，影响免疫抗原性风险、给药频率和监管预期。蛋白水解物包括分子黏合剂和 PROTAC，它们具有不同的选择性特征和临床前评估途径。同时，小分子抑制剂涵盖从 PARP 抑制剂到蛋白酶体抑制剂和蛋白酪氨酸激酶抑制剂等多种类型，每种抑制剂都需要不同的药理特性和伴随诊断方法。

区域洞察：分析美洲、欧洲、中东和非洲以及亚太地区的市场动态将如何影响开发、市场准入和供应链策略。

地理洞察对于全球规划至关重要，因为区域趋势会影响从临床开发策略到供应链配置以及与支付方互动等各方面。美洲地区拥有不同的监管路径和支付体系，但往往在创新治疗方法的早期应用和基于价值的合约试点方面处于领先。因此，製造商应优先考虑产生可靠的临床证据和支付方参与框架，以证明其疗效和长期结果。北美地区的生产能力和先进的临床试验基础设施支持复杂治疗方法的快速患者招募，但国内采购和关税因素可能会影响后期生产的位置。

行业领导者正在采取策略性企业行动并进行产能投资，以将技术创新转化为具有临床意义的治疗方法和永续的商业性优势。

业界领导企业正采取各种策略性倡议，以充分发挥标靶治疗的潜力，同时应对相关的科学和商业性复杂性。许多机构正在加速投资于标准化偶联技术、抗体设计和降解化学的平台，以降低技术风险并加快临床试验进程。他们还与生物技术公司、学术机构和合约开发组织建立合作关係，以利用这些机构的专业知识，而无需承担全部内部开发成本。这些伙伴关係模式支持灵活的产能扩张，并且能够快速回应特定疗法的需求波动。

针对标靶治疗领导企业的实用跨职能建议，包括整合生物标记主导的开发、弹性供应链和以病人为中心的商业化。

致力于最大化标靶治疗价值的领导者应实施切实可行的跨职能措施，协调科学重点、商业性现实和供应链韧性。首先，在临床开发早期阶段整合生物标记策略和卫生经济学，确保试验能够产生支付方所需的证据。协调这些职能可以减少后期延误，并增强价值提案。其次，透过选择区域契约製造合作伙伴并设计能够实现关键组件互换性的平台，实现采购和生产多元化，从而降低关税衝击和短期供应中断带来的风险。

透明的混合方法研究框架，结合相关利益者访谈、临床和专利分析、供应链图谱绘製以及情境检验，确保了研究结果的可靠性。

本研究融合了定性和定量方法，旨在深入了解标靶治疗的动态发展。它结合了与关键相关人员的直接对话、系统的二手资料研究和技术综述。一手研究包括对临床研究人员、监管专家、生产经理、支付方和分销专家进行深度访谈，以揭示实际操作中的限制和新兴的最佳实践。这些访谈构成了主题编码的基础，识别出反覆出现的营运痛点，例如低温运输薄弱环节、监管差异以及支付方的证据要求。

从综合视角和策略角度分析科学进步、供应链因素和支付方期望如何决定标靶治疗的成功。

总之，标靶治疗领域正处于转折点，科学创新、营运复杂性和商业性审查在此交汇融合。抗体药物复合体、单株抗体、蛋白质降解剂和小分子抑制剂的进步拓展了研发人员的工具箱，但要实现治疗和商业性的成功，需要研发、生产、监管事务和医保支付等各环节的协调合作。贸易和关税的变化带来了新的营运挑战，需要更详细的供应链规划和策略采购决策；而监管和报销框架的区域差异则要求量身定制的市场推广策略。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧应用于生物标记发现，以实现个人化标靶治疗
  • 针对多种肿瘤抗原的双特异性抗体的出现，有助于克服抗药性机制
  • 扩大标靶表观遗传修饰因子的小分子抑制剂在精准肿瘤学的应用
  • 监管奖励促进针对罕见致癌性突变的小众标靶治疗的开发
  • 透过位点特异性有效载荷偶联技术推进抗体药物复合体(ADC) 的创新
  • 数位生物标记合作投资趋势，旨在优化标靶治疗的患者分层
  • 一种个人化的新抗原疫苗平台，可与标靶治疗方案互补，以增强免疫反应。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按产品类型标靶治疗市场

  • 抗体药物复合体
    • CD22标靶
    • HER2靶点
  • 单株抗体
    • 嵌合体体
    • 完全人类
    • 人性化
  • 蛋白质降解剂
    • 分子黏合剂
    • 进攻
  • 小分子抑制剂
    • PARP抑制剂
    • 蛋白酶体抑制剂
    • 蛋白酪氨酸激酶抑制剂

第九章 按给药途径标靶治疗市场

  • 静脉注射
  • 口服
  • 皮下注射

第十章 按最终用户标靶治疗市场

  • 居家医疗
  • 医院药房
  • 零售药房
  • 专科诊所

第十一章 各地区的标靶治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章标靶治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国标靶治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
    • AbbVie Inc.
    • Amgen Inc.
    • Johnson & Johnson
    • Gilead Sciences, Inc.
Product Code: MRR-CA7E340319CF

The Targeted Therapy Market is projected to grow by USD 121.80 billion at a CAGR of 7.72% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 67.16 billion
Estimated Year [2025] USD 72.41 billion
Forecast Year [2032] USD 121.80 billion
CAGR (%) 7.72%

A concise orientation to the evolving targeted therapy ecosystem that connects scientific breakthroughs with operational, regulatory, and commercial imperatives for leaders

Targeted therapies are redefining how clinicians and developers approach complex diseases by aligning molecular insights with therapeutic design. Recent scientific advances have pushed modalities such as antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors from proof-of-concept into increasingly sophisticated clinical programs. As a result, stakeholders across discovery, development, and commercialization must adapt to faster iteration cycles, deeper biomarker integration, and more nuanced regulatory dialogues. This introduction frames the critical forces shaping the field and sets expectations for near-term tactical priorities.

Investors and R&D leaders now judge programs not only on biological rationale but also on manufacturability, supply chain robustness, and reimbursement pathways. Clinical teams emphasize patient selection and companion diagnostics to improve trial efficiency and therapeutic impact, while manufacturing groups prioritize platform consistency and scalable processes to reduce variability. In parallel, payers and health systems increasingly demand real-world evidence and outcomes-based contracting to justify premium pricing for novel modalities. These converging pressures create both friction and opportunity: organizations that align scientific excellence with operational execution will capture disproportionate value.

Transitioning from early discovery to widespread adoption requires deliberate alignment across cross-functional teams. This report begins by outlining transformational shifts in science and market structure, then explores regulatory and trade headwinds, segment-level implications, regional dynamics, and strategic recommendations intended to inform immediate actions and longer-term planning.

How converging scientific, regulatory, and commercial innovations are reshaping therapeutic modalities and operational priorities across the targeted therapy landscape

The last several years have produced transformative shifts that are remapping the targeted therapy landscape, accelerating novel modalities while raising new operational imperatives. Technological advances in protein engineering and conjugation chemistry have elevated antibody drug conjugates into a leading modality for delivering cytotoxic payloads selectively, while monoclonal antibody evolution toward fully human and humanized constructs has reduced immunogenicity and enabled longer treatment windows. Simultaneously, the maturation of targeted protein degradation-through molecular glues and proteolysis targeting chimeras-introduces routes to modulate previously intractable targets, broadening the therapeutic opportunity set.

These scientific gains intersect with innovations in small molecule design, where tailored inhibitors such as PARP, proteasome, and tyrosine kinase agents offer complementary mechanisms for multi-modal regimens. At the same time, digital tools and artificial intelligence accelerate lead identification and predictive modeling, shortening development cycles and improving candidate selection. Regulatory frameworks are adapting to these modalities by offering more targeted guidance on combination approaches, biomarker-driven approvals, and adaptive trial designs, yet variability in regional expectations is prompting sponsors to design programs with parallel regulatory engagement.

Commercially, payers and providers are demanding clearer evidence of comparative effectiveness and value-based pricing models, which drives closer alignment between clinical development and health economics planning. Manufacturing and cold-chain logistics improvements are enabling new route-of-administration strategies, particularly increased attention to subcutaneous and home-administered formulations that improve patient convenience and lower system costs. The net effect is a landscape where innovation is rapid, but success increasingly depends on integrated scientific, regulatory, and commercial execution.

Analyzing the cumulative trade and tariff dynamics announced for 2025 and their cascading effects on biopharmaceutical sourcing, manufacturing, and patient access strategies

The introduction of cumulative tariffs and trade adjustments announced for 2025 has introduced a new layer of complexity across the targeted therapy value chain, affecting sourcing, manufacturing, and distribution decisions. Tariff changes on raw materials, specialized reagents, and certain biologics-related components increase effective landed costs and prompt procurement teams to reassess supplier footprints. These pressures often translate into longer negotiation cycles with contract manufacturers and a renewed emphasis on dual-sourcing strategies to maintain clinical and commercial continuity. Moreover, tariff-driven cost pressures influence capital allocation decisions for new facility builds and technology investments.

Manufacturers facing increased import duties for key inputs have adopted several mitigation strategies, including reshoring select production steps closer to end markets, qualifying local suppliers where possible, and redesigning supply chains to reduce reliance on tariff-exposed nodes. Regulatory harmonization efforts and free trade agreements remain uneven, so companies must navigate a patchwork of customs procedures and compliance requirements that can delay batch release and increase lead times. For programs reliant on time-sensitive biologics or cold-chain logistics, even modest tariff-related delays can disrupt clinical trial timelines and product launches, which in turn impacts forecasting and inventory policies at distributors and hospitals.

In response, senior leaders are recalibrating vendor contracts to include tariff pass-through clauses and investing in supply chain transparency tools to model exposure across scenarios. Strategic sourcing now requires closer collaboration between commercial, regulatory, and procurement teams to optimize total landed cost while preserving product integrity and patient access. The cumulative effect of these trade measures is to accelerate existing trends toward regionalization of production and enhanced supply chain resilience, with implications for pricing strategies, partner selection, and manufacturing footprint optimization.

Segment-focused insights that integrate product modality, administration route, and end-user delivery considerations to inform development prioritization and commercialization tactics

Effective segmentation clarifies where therapeutic and commercial returns will concentrate and informs portfolio prioritization across product, administration route, and end-user domains. When viewed through product type, the landscape differentiates antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors, each with distinct development, manufacturing, and commercialization demands. Within antibody drug conjugates, agents directed at CD22 and HER2 represent divergent payload selection and target engagement strategies that influence linker chemistry and cytotoxic payload choices. Monoclonal antibodies subdivide into chimeric, fully human, and humanized formats, affecting immunogenicity risk, dosing frequency, and regulatory expectations. Protein degraders encompass molecular glues and PROTACs, which differ in selectivity profiles and preclinical assessment pathways, while small molecule inhibitors range from PARP inhibitors to proteasome and tyrosine kinase inhibitors, each requiring different pharmacology and companion diagnostic approaches.

Routes of administration add another layer of strategic differentiation, spanning intravenous, oral, and subcutaneous delivery. Intravenous therapies often necessitate hospital-based administration and complex cold-chain logistics, while oral agents increase outpatient convenience and adherence considerations. Subcutaneous formulations are gaining prominence as a patient-friendly alternative that can reduce infusion center burden and enable home-based care models. End-user segmentation further refines go-to-market and support needs, with home care, hospital pharmacy, retail pharmacy, and specialty clinics each presenting unique distribution, reimbursement, and patient support requirements. Home care models require robust patient education and remote monitoring, hospital pharmacy environments demand streamlined formulary access and inpatient logistics, retail pharmacies offer broad outpatient reach but require clear dispensing pathways, and specialty clinics provide concentrated clinical expertise and can facilitate complex care pathways.

Understanding the intersection across these dimensions enables sponsors to tailor development and commercialization tactics, align clinical trial designs with likely real-world administration settings, and structure stakeholder engagement plans that reflect where and how therapies will be delivered and reimbursed.

Regional intelligence spotlighting how Americas, Europe Middle East & Africa, and Asia-Pacific market dynamics influence development, access, and supply chain strategies

Regional dynamics shape everything from clinical development strategies to supply chain configuration and payer interactions, making geographic insight indispensable for global planning. In the Americas, regulatory pathways and payer systems are highly varied, but the region often leads in early adoption of innovative therapies and value-based contracting pilots; manufacturers should therefore prioritize robust clinical evidence generation and payer engagement frameworks that demonstrate comparative effectiveness and long-term outcomes. North American manufacturing capacity and advanced clinical trial infrastructure support rapid enrollment for complex modalities, but domestic sourcing and tariff considerations can influence where late-stage production is sited.

Europe, Middle East & Africa present a mosaic of regulatory expectations and reimbursement mechanisms that require tailored market entry strategies. European health technology assessment bodies frequently demand rigorous health economic data and may negotiate centralized procurement for high-cost therapies, while reimbursement timelines can vary substantially between markets. The Middle East and Africa offer pockets of high unmet need and concentrated procurement initiatives, yet accessibility and local regulatory capacity vary widely, prompting sponsors to adopt differentiated commercial models and targeted access programs.

Asia-Pacific continues to expand clinical development capacity and local manufacturing capabilities, with several markets emphasizing domestic innovation and regulatory modernization. Countries across the region are increasingly receptive to data generated from local patient populations and are investing in infrastructure that supports large-scale oncology and specialty care trials. Pricing and reimbursement policies differ markedly between public and private systems, so sponsors should design regional strategies that balance localized evidence generation with efficient regulatory pathways. Across regions, the convergence of digital health adoption and decentralized trial methodologies presents opportunities to harmonize patient recruitment, monitoring, and long-term outcomes collection at scale.

Strategic corporate moves and capability investments industry leaders are deploying to convert modality innovation into clinically meaningful therapies and sustainable commercial advantage

Industry leaders are deploying a range of strategic moves to capture the promise of targeted therapies while managing the attendant scientific and commercial complexity. Many organizations are accelerating platform investments that standardize conjugation technologies, antibody engineering, and degradation chemistries to reduce technical risk and shorten time to clinic. Others are forging collaborations across biotech partners, academic centers, and contract development organizations to access specialized capabilities without assuming the full cost of in-house development. These partnership models support flexible capacity scaling and enable rapid response as modality-specific demand shifts.

Commercial strategies now emphasize integrated launch planning that brings clinical development, regulatory engagement, health economics, and market access teams together earlier in the lifecycle. Leaders invest in real-world evidence generation and outcomes tracking to demonstrate value to payers and providers, and they deploy patient support services to promote adherence and optimize clinical outcomes. On the manufacturing front, companies are diversifying supplier bases, qualifying secondary manufacturing sites, and expanding fill-finish capabilities to mitigate supply disruption risks.

Pipeline management has become more selective, with sponsors prioritizing indications and combinations that maximize therapeutic differentiation and align with feasible reimbursement pathways. Talent strategies focus on hiring scientists and executives with cross-functional experience in biologics, regulatory affairs, and commercial operations. The net effect is a more disciplined, partnership-driven, and execution-focused industry posture that seeks to translate scientific promise into durable therapeutic and commercial success.

Actionable cross-functional recommendations to align biomarker-driven development, resilient supply chains, and patient-centric commercialization for leaders in targeted therapy

Leaders seeking to maximize value in targeted therapy should adopt a set of actionable, cross-functional measures that align scientific priorities with commercial realities and supply chain resilience. First, integrate biomarker strategy and health economics early in clinical development to ensure trials generate the evidence payers require; connecting these functions reduces later-stage delays and strengthens value narratives. Second, diversify sourcing and manufacturing by qualifying regional contract manufacturing partners and by designing platforms that permit interchangeability of critical components; this reduces exposure to tariff shocks and short-term supply interruptions.

Third, prioritize patient-centric administration strategies by investing in subcutaneous formulation development and patient support infrastructure that enable home-based care where clinically appropriate. Fourth, pursue strategic collaborations to access specialized modalities such as molecular glues or PROTAC chemistry while preserving optionality through staged investment and clear milestone gating. Fifth, engage proactively with regulatory authorities across key jurisdictions to align on adaptive trial designs and biomarker-driven approval pathways, reducing the risk of divergent requirements and costly trial amendments.

Finally, operationalize data and analytics to monitor supply chain exposure, clinical trial progress, and real-world outcomes in near real time; these capabilities enable faster course corrections and more informed commercial rollouts. Collectively, these actions help organizations navigate complexity, preserve optionality, and accelerate the translation of scientific advances into patient benefit and sustained commercial performance.

A transparent mixed-methods research framework combining stakeholder interviews, clinical and patent analysis, supply chain mapping, and scenario-based validation to ensure robust insights

This research synthesizes qualitative and quantitative approaches to produce a nuanced view of targeted therapy dynamics, combining primary stakeholder engagement with structured secondary analysis and technical review. Primary research included in-depth interviews with clinical investigators, regulatory specialists, manufacturing leaders, payers, and distribution experts to surface practical constraints and emerging best practices. These dialogues informed thematic coding and identified recurring operational pain points such as cold-chain vulnerability, regulatory heterogeneity, and payer evidence expectations.

Secondary analysis encompassed peer-reviewed literature, clinical trial registries, patent filings, and publicly available regulatory guidance to validate scientific trends and modality-specific technical requirements. Supply chain mapping leveraged public customs data and industry logistics reporting to trace typical component flows and identify tariff-sensitive nodes. Additionally, product development case studies and manufacturing due diligence informed assessments of platform readiness and scale-up risk.

Analytical methods included cross-sectional synthesis to compare modality characteristics, scenario modeling to evaluate tariff and supply disruption impacts, and triangulation across data sources to ensure robustness. Wherever possible, findings were stress-tested against recent regulatory decisions, clinical readouts, and announced capacity investments to ensure recommendations reflect operational realities. This mixed-methods approach offers a replicable framework for translating scientific advances into strategic priorities while acknowledging uncertainty and preserving managerial flexibility.

Synthesis and strategic outlook summarizing how scientific advances, supply chain considerations, and payer expectations will determine success in targeted therapy

In closing, the targeted therapy field stands at an inflection point where scientific ingenuity meets operational complexity and commercial scrutiny. Advances across antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors have expanded the toolkit available to developers, but realizing therapeutic and commercial promise requires coordinated action across development, manufacturing, regulatory, and payer engagement functions. Trade and tariff changes add a new operational layer that compels more granular supply chain planning and strategic sourcing decisions, while regional heterogeneity in regulatory and reimbursement frameworks necessitates tailored go-to-market approaches.

Organizations that invest early in integrated evidence generation, diversify manufacturing footprints, and design patient-centered administration strategies will improve their odds of successful adoption. Partnerships remain a powerful mechanism to access specialized capabilities and to share risk, and leaders who combine platform investments with selective external collaborations are best positioned to scale efficiently. Ultimately, targeted therapies will continue to reshape treatment paradigms, but success will hinge on the ability to translate molecular innovation into reproducible clinical outcomes, reliable supply, and validated value to payers and providers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence in biomarker discovery for personalized targeted therapies
  • 5.2. Emergence of bispecific antibodies targeting multiple tumor antigens to overcome resistance mechanisms
  • 5.3. Expansion of small molecule inhibitors targeting epigenetic modifiers in precision oncology
  • 5.4. Regulatory incentives accelerating development of niche targeted therapies for rare oncogenic mutations
  • 5.5. Momentum in antibody-drug conjugate innovation with site-specific payload conjugation techniques
  • 5.6. Investment trends in digital biomarker partnerships to optimize patient stratification for targeted therapeutics
  • 5.7. Personalized neoantigen vaccine platforms complementing targeted therapy regimens to enhance immune response

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Therapy Market, by Product Type

  • 8.1. Antibody Drug Conjugates
    • 8.1.1. Cd22 Directed
    • 8.1.2. Her2 Directed
  • 8.2. Monoclonal Antibodies
    • 8.2.1. Chimeric
    • 8.2.2. Fully Human
    • 8.2.3. Humanized
  • 8.3. Protein Degraders
    • 8.3.1. Molecular Glues
    • 8.3.2. Protacs
  • 8.4. Small Molecule Inhibitors
    • 8.4.1. Parp Inhibitors
    • 8.4.2. Proteasome Inhibitors
    • 8.4.3. Tyrosine Kinase Inhibitors

9. Targeted Therapy Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Targeted Therapy Market, by End User

  • 10.1. Home Care
  • 10.2. Hospital Pharmacy
  • 10.3. Retail Pharmacy
  • 10.4. Specialty Clinic

11. Targeted Therapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Targeted Therapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Targeted Therapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. F. Hoffmann-La Roche Ltd
    • 14.3.2. Novartis AG
    • 14.3.3. Pfizer Inc.
    • 14.3.4. Merck & Co., Inc.
    • 14.3.5. Bristol-Myers Squibb Company
    • 14.3.6. AstraZeneca PLC
    • 14.3.7. AbbVie Inc.
    • 14.3.8. Amgen Inc.
    • 14.3.9. Johnson & Johnson
    • 14.3.10. Gilead Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GCC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. GCC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. GCC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 298. GCC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 299. GCC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 300. GCC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 301. GCC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 302. GCC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 303. GCC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 304. GCC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 305. GCC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. GCC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. GCC TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. GCC TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. BRICS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. BRICS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. BRICS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. BRICS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. BRICS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 330. BRICS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 331. BRICS TARGETED THERAPY MARKE